三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

交易中 10-01 14:35:05 EDT

259.13

-6.66

-2.50%

最高271.77	最低254.77	成交量32.37万
今开261.76	昨收265.79	日振幅6.40%
总市值5.89亿	流通市值5.89亿	总股本227.45万
成交额8,448万	换手率14.23%	流通股本227.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":259.1322,"timestamp":1790879665527,"preClose":265.79,"halted":0,"volume":323650,"delay":0,"changeRate":-0.02504909891267545,"floatShares":2274486,"shares":2274486,"eps":0,"marketStatus":"交易中","change":-6.6578,"latestTime":"10-01 14:35:05 EDT","open":261.76,"high":271.7723,"low":254.77,"amount":84478902.918,"amplitude":0.063969,"askPrice":260.78,"askSize":200,"bidPrice":259.74,"bidSize":30,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.79,"sharesOutstanding":3024486,"nav":260.661,"aum":592869955.42,"dividendRate":0.003487,"bidAskSpread":0.003436,"preHourTrading":{"tag":"盘前","latestPrice":261.6,"preClose":265.79,"latestTime":"09:29 EDT","volume":2318,"amount":612617.1732800001,"timestamp":1790861345993,"change":-4.19,"changeRate":-0.015764,"amplitude":0.02976},"postHourTrading":{"tag":"盘后","latestPrice":266.5,"preClose":265.79,"latestTime":"19:59 EDT","volume":2105,"amount":559351.6497,"timestamp":1790812786487,"change":0.71,"changeRate":0.002671,"amplitude":0.007525},"volumeRatio":1.269718,"impliedVol":0.9385,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"2671361204","title":"ADP报告：自5月以来，招聘活动首次加速，其中教育、医疗保健以及休闲和酒店行业引领增长。金融活动以及专业和商业服务行业则","url":"https://stock-news.laohu8.com/highlight/detail?id=2671361204","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671361204?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:21","pubTimestamp":1790770861,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PEJ","LABU","BK4585","XLV","159940","NOBL","CGVV","BK4550","VHT","BK4581","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671272100","title":"罗氏（RHHBY）推出三合一新生儿遗传病筛查试剂盒 多发性硬化症口服新药芬布替尼获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2671272100","media":"金吾财讯","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671272100?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:45","pubTimestamp":1790757948,"startTime":"0","endTime":"0","summary":"金吾财讯 | 罗氏 宣布，其诊断业务旗下子公司TIB MOLBIOL正式在认可欧盟CE标志的国家推出LightMix Newborn TREC/SMN1/HBB基因检测试剂盒。该产品已获得体外诊断医疗器械法规认证，标志着罗氏在早期诊断与新生儿筛查领域的进一步拓展。此外，罗氏同时宣布，美国食品药品监督管理局已正式受理其在研药物芬布替尼的新药申请，并授予优先审评资格。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306639","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","HRTS","BK4585","BK4588","RHHBY","LABU","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671506275","title":"亿帆医药：Ryzneuta增加中国境内生产场地获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2671506275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671506275?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:43","pubTimestamp":1790750631,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224170","title":"港股异动 | 和黄医药(00013)涨超3% 宣布向FDA提交沃瑞沙®联合泰瑞沙®联合疗法的新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224170","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224170?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:50","pubTimestamp":1790736612,"startTime":"0","endTime":"0","summary":"消息面上，9月29日，和黄医药发布公告，阿斯利康已向美国食品药品监督管理局提交沃瑞沙 和泰瑞沙 的联合疗法的新药上市申请，用于治疗接受一种表皮生长因子受体酪氨酸激酶抑制剂治疗期间或之后出现疾病进展的伴有MET过表达或扩增的局部晚期或转移性非小细胞肺癌患者。SAFFRON全球III期研究的数据支持了该项新药上市申请。据悉，沃瑞沙由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1191","BK1588","BK4588","IPOS","KCAI","BK4585","00013","LABU","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671294611","title":"健友股份：阿达木单抗40mg/0.4mL获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2671294611","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671294611?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:01","pubTimestamp":1790668898,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670578258","title":"艾伯维（ABBV）旗下创新帕金森病治疗药物Juvmo片剂上市申请获FDA正式批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670578258","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670578258?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:15","pubTimestamp":1790601343,"startTime":"0","endTime":"0","summary":"此次获批基于成功的3期TEMPO临床项目。艾伯维官方表示，计划于2026年10月正式将Juvmo投放美国市场，供帕金森病患者使用。据介绍，该药是艾伯维此前斥资87亿美元收购Cerevel Therapeutics公司后迎来的首个重大研发成果落地，进一步夯实了其在神经科学领域的全球领先地位。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","SG9999001440.SGD","LU2087621335.USD","LU0882574055.USD","LU0211327993.USD","LU0289739343.SGD","ABBV","GLAM","LU0289961442.SGD","IE00BSNM7G36.USD","IXJ","LU1929549753.HKD","LU1720051017.SGD","LU1093756168.USD","TRUH","LU1037948897.HKD","LU0942090050.USD","LU1718418525.SGD","LU1244550577.SGD","VHT","XLV","PPH","MEDX","RXL","IE0002141913.USD","BK4533","BK4581","FHLC","LU0203347892.USD","IE0009355771.USD","LU1267930573.SGD","LU1934455863.HKD","IPOS","IYH","PJP","FTXH","LABU","LU2125909247.SGD","LU1496350502.SGD","LU1989772923.USD","AGNG","LU1839511570.USD","LU0203345920.USD","LU1934455277.USD","LU0124676726.USD","IE00B19Z3B42.SGD","LU0128525929.USD","IBRN","LU0738911758.USD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670232662","title":"美国食品药品监督管理局（FDA）批准艾伯维的JUVMO™（tavapadon）用于治疗帕金森病。","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232662","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670232662?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:04","pubTimestamp":1790597042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4588","159151","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670262238","title":"德展健康(000813.SZ)子公司创新药WYY026B注射液获得美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670262238","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670262238?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:08","pubTimestamp":1790586484,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德展健康 发布公告，公司全资子公司北京红惠新医药科技有限公司于近日收到美国食品药品监督管理局通知，由红惠新申报的WYY026B注射液药品临床试验申请已获得美国FDA批准，开展相关临床研究。本次WYY026B注射液在美国的临床试验申请获批，是该款药品研发进程中的重要进展，将进一步提升公司在心脑血管药品研发领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0060","BK4588","BMED","IBBJ","BK4585","IBBQ","LABU","MEDX","BK0239","000813","159992","PSYK","MDTX","BK0114","BK1161","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280512","title":"健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280512","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670280512?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:36","pubTimestamp":1790584569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司香港健友实业有限公司(以下简称“香港健友”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的维生素B1注射液200mg/2mL(100mg/mL)的ANDA批准通知(ANDA号：213131)。新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0239","LABU","BK0186","BK0046","BK4588","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670284234","title":"信达生物：IBI363临床研究获美国FDA批准新增非鳞状非小细胞肺癌研究人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2670284234","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670284234?lang=zh_cn&edition=full","pubTime":"2026-09-28 15:24","pubTimestamp":1790580265,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441624","title":"Prime Medicine（PRME）盘前涨10.45% FDA批准其PM647的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441624","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670441624?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:33","pubTimestamp":1790328824,"startTime":"0","endTime":"0","summary":"金吾财讯 | Prime Medicine（PRME）盘前涨10.45%，报3.391美元。消息面上，美国食品药品监督管理局（FDA）批准其PM647的新药临床试验申请（IND）。获批使Prime Medicine能够启动一项评估PM647用于患有该遗传性疾病成人患者的1/2期试验。预计将于2027年获得初步临床数据。PM647是一种用于治疗α-1抗胰蛋白酶缺乏症的实验性基因编辑疗法。PM647旨在修复导致α-1抗胰蛋白酶缺乏症的基因突变。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306480","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","MDTX","PSYK","PRME","BK4588","BK4585","IBBQ","LABU","IBBJ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670178448","title":"夏邑人速看!延续实施扩大社会保险补贴范围政策，直补个人，最长可领12个月!","url":"https://stock-news.laohu8.com/highlight/detail?id=2670178448","media":"掌握夏邑","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670178448?lang=zh_cn&edition=full","pubTime":"2026-09-25 13:48","pubTimestamp":1790315280,"startTime":"0","endTime":"0","summary":"4.无合同年限限制:本次政策不强制要求一年以上劳动合同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-25/doc-iniszmnc4546647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","BK4585","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670941456","title":"兰州市自明年起不再向用人单位收取退休人员大额医疗保险费","url":"https://stock-news.laohu8.com/highlight/detail?id=2670941456","media":"中国兰州网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670941456?lang=zh_cn&edition=full","pubTime":"2026-09-25 09:41","pubTimestamp":1790300460,"startTime":"0","endTime":"0","summary":"记者9月24日从兰州市医保局获悉，自2027年1月1日起，全市企业退休人员大额医疗保险费单位缴费部分不再收取，个人缴费费率及缴费方式不变；灵活就业退休人员大额医疗保险个人缴费费率减半。用人单位特别是小微企业，不再缴纳退休人员大额医疗保险费，减轻用工成本，持续优化营商环境。灵活就业退休人员大额医疗保险个人缴费费率由0.5%调整为0.25%，全年人均减轻缴费负担226.32元，有效减轻参保群众经济负担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-25/doc-inisyywi4652149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","BK4585","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670901764","title":"美国 FDA 批准一款肾病药物后，默沙东股价持平但成交量激增，最新上涨 0.50%，报 148.81 美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2670901764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670901764?lang=zh_cn&edition=full","pubTime":"2026-09-25 03:29","pubTimestamp":1790278155,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","UUP","UDN","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669946360","title":"遭FDA进口禁令，圣诺生物美国业务亮起红灯","url":"https://stock-news.laohu8.com/highlight/detail?id=2669946360","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669946360?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:37","pubTimestamp":1790239020,"startTime":"0","endTime":"0","summary":"多肽CDMO企业圣诺生物子公司圣诺制药接受FDA现场检查之后，收到483观察表，随后被列入进口禁令名单。随后企业被纳入FDA进口禁令名单，产品出口美国将受到限制。截至目前公司尚未收到FDA警告信以及最终官方处置结论，但禁令已经客观形成约束。FDA的现场检查结果直接决定企业能否拿到海外订单。后续有两大看点，一是企业整改的进度，能否尽快消除FDA提出的各项缺陷、解除进口限制；二是海外客户信心是否发生动摇，会不会出现订单流失。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-24/doc-inisxnuv5179837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688117","LABU","BK4585","BK0239","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669457112","title":"全球多癌早筛闯过FDA专家这一关，华大基因早筛业务迎来下一轮产品兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2669457112","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669457112?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:16","pubTimestamp":1790234160,"startTime":"0","endTime":"0","summary":"三项表决整体指向建议批准Galleri用于 50 岁及以上人群的多癌筛查。这次投票的意义在于，它是外界观察FDA对多癌筛查这一类产品持何审评尺度的窗口，尺度松紧会直接影响后续所有同类产品的申报预期。同期净亏损1.102亿美元，调整后EBITDA为负9030万美元；截至6月30日，现金及短期有价证券合计8.616亿美元。FDA未上诉，并于2025年","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-24/doc-inisxhpc4995817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK0196","BK0221","BK4585","BK0046","BK0197","300676","LABU","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437927","title":"晶泰向美国FDA提交KQTD-126新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669437927?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:38","pubTimestamp":1790210290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","BK4585","BK4588","BMED","LABU","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150507917","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1150507917","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150507917?lang=zh_cn&edition=full","pubTime":"2026-09-23 04:53","pubTimestamp":1790110396,"startTime":"0","endTime":"0","summary":"美东时间0638——诺和诺德在资本市场日活动上公布的多元化战略及模糊的中期销售目标，令投资者颇感失望，AlphaValue分析师Abhishek Raval如此写道。\"面对对单一分子的过度依赖，激进而大规模的业务多元化押注，加上无可挑剔的商业执行力，已是当务之急。\"然而，市场对此心存疑虑，Raval表示。AlphaValue对该丹麦药企股票给予买入评级，目标价450丹麦克朗。股价微跌0.2%，报259.40克朗。这家法意合资的眼镜集团近期因市场担心该领域将涌入新竞争者而承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XBI","XLV","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113321759","title":"医疗保健板块市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1113321759","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113321759?lang=zh_cn&edition=full","pubTime":"2026-09-23 00:23","pubTimestamp":1790094199,"startTime":"0","endTime":"0","summary":"0638 GMT - 诺和诺德的资本市场日活动公布了一系列消息，其中包括业务多元化计划及一个略显模糊的中期销售目标。然而，AlphaValue分析师阿布希谢克·拉瓦尔指出，这些内容并未令投资者感到满意。不过，市场对此仍心存疑虑。AlphaValue给予这家丹麦制药商的股票“买入”评级，目标价为450丹麦克朗。该股现跌0.2%，报259.40克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","LABU","BK4581","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711242","title":"健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711242","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669711242?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:17","pubTimestamp":1790065020,"startTime":"0","endTime":"0","summary":"9月22日，健友股份(603707.SH)公告称，公司子公司Meitheal Pharmaceuticals Inc.近日收到美国FDA签发的硫酸阿米卡星注射液(500mg/2mL、1g/4mL)增加生产场地的批件，批准在南京健友生化制 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4588","LABU","BK0186","603707","BK0239","BK4585","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0501},{"period":"1month","weight":-0.103},{"period":"3month","weight":-0.1241},{"period":"6month","weight":0.5485},{"period":"1year","weight":1.8393},{"period":"ytd","weight":0.6675}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.545455,"avgChangeRate":0.013816},{"month":6,"riseRate":0.75,"avgChangeRate":0.158596},{"month":7,"riseRate":0.583333,"avgChangeRate":0.031304},{"month":8,"riseRate":0.666667,"avgChangeRate":0.021527},{"month":9,"riseRate":0.25,"avgChangeRate":-0.06835},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}